- Previous Close
7.21 - Open
7.08 - Bid 7.08 x 100
- Ask 7.43 x 100
- Day's Range
6.89 - 7.41 - 52 Week Range
2.22 - 11.78 - Volume
40,727 - Avg. Volume
221,683 - Market Cap (intraday)
80.742M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-0.71 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.00
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
www.nutriband.comRecent News: NTRB
View MorePerformance Overview: NTRB
Trailing total returns as of 2/28/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NTRB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NTRB
View MoreValuation Measures
Market Cap
80.30M
Enterprise Value
74.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
35.44
Price/Book (mrq)
7.15
Enterprise Value/Revenue
37.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.79%
Return on Equity (ttm)
-80.82%
Revenue (ttm)
2.02M
Net Income Avi to Common (ttm)
-6.85M
Diluted EPS (ttm)
-0.71
Balance Sheet and Cash Flow
Total Cash (mrq)
5.7M
Total Debt/Equity (mrq)
1.79%
Levered Free Cash Flow (ttm)
-2.17M